Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10444305" target="_blank" >RIV/00669806:_____/22:10444305 - isvavai.cz</a>
Alternative codes found
RIV/00159816:_____/22:00076271 RIV/00064203:_____/22:10444305 RIV/00216208:11130/22:10444305 RIV/00216208:11140/22:10444305 and 3 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=jE~SwYtHu8" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=jE~SwYtHu8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/cea.14182" target="_blank" >10.1111/cea.14182</a>

Result language
angličtina
Original language name
Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema
Original language description
Hereditary angioedema (HAE) is a rare condition which manifests as repeated episodes of localized subcutaneous or submucosal oedema . Oedemas involving the upper airways carry the risk of asphyxiation and death. The aim of this study is to present our clinical experience of icatibant and C1 inhibitor use for treating HAE-1/2 laryngeal attacks(LA).To our knowledge, this is the first direct comparison of these treatment approaches for LA.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)